EUVIMEDEUVIMED entdecken
Querschnittstudie

Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study

Shu-Jun Gu iD, Liu Xu, Hong-Kun Zhou, Jie Yang

Journal of Proteome Research · 2026

DOI: 10.1021/acs.jproteome.5c00615 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Journal of Proteome Research, 2026. Verfasst von Shu-Jun Gu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing 314000 Zhejiang, China. Hauptthemen laut MEDLINE: CA-19-9 Antigen, Carcinoma, Pancreatic Ductal, Metabolomics, Biomarkers, Tumor. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province, National Oncology Clinical Key Speciality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) with negative carbohydrate antigen 19-9 (CA19-9) lacks effective diagnostic and monitoring indicators. We aimed to identify metabolic characteristics in such patients through metabolomics and explored potential plasma biomarkers. In this study, untargeted metabolomics analysis was performed on plasma samples from 30 healthy controls and 30 CA19-9 positive and 30 CA19-9 negative PDAC patients by using liquid chromatograph-mass spectrometer (LC-MS) technology. Compared with healthy controls, 36 differential metabolites were upregulated, and 3 differential metabolites were downregulated in the plasma of CA19-9 negative PDAC patients. Four upregulated differential metabolites, including palmitic amide, dolichol phosphate, cholesteryl acetate, and vitamin A2 aldehyde, were potential biomarkers for diagnosing CA19-9 negative PDAC patients. Enrichment analysis of KEGG pathways showed that glycine and threonine metabolism, tyrosine and tryptophan biosynthesis, thiamine metabolism, etc., were disrupted in CA19-9 negative PDAC patients. In summary, we determined the metabolic heterogeneity in PDAC patients with normal CA19-9 levels. The detected metabolic biomarkers may offer new approaches for the clinical early diagnosis of CA19-9 negative PDAC in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CA-19-9 AntigenCarcinoma, Pancreatic DuctalMetabolomicsBiomarkers, TumorPancreatic NeoplasmsHumansFemaleMiddle AgedMaleCross-Sectional StudiesAgedChromatography, LiquidCase-Control StudiesMetabolome

Stichwörter der Autor:innen

carbohydrate antigen 19-9liquid chromatograph−mass spectrometermetabolomicspancreatic ductal adenocarcinoma

Substanzen

CA-19-9 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Respiratory Medicine, First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing 314000 Zhejiang, China.
  • Department of Hepatobiliary and Pancreatic Surgery, First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing 314000 Zhejiang, China.

ORCID-Profile: Shu-Jun Gu

Förderung

  • Medical Science and Technology Project of Zhejiang Province
  • National Oncology Clinical Key Speciality

Zitieren

APA

Gu, S. J., Xu, L., Zhou, H. K., & Yang, J. (2026). Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.5c00615

Vancouver

Gu SJ, Xu L, Zhou HK, Yang J. Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study. Journal of Proteome Research. 2026. doi:10.1021/acs.jproteome.5c00615

BibTeX
@article{Gu2026,
  author = {Gu, Shu-Jun and Xu, Liu and Zhou, Hong-Kun and Yang, Jie},
  title = {Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study},
  journal = {Journal of Proteome Research},
  year = {2026},
  doi = {10.1021/acs.jproteome.5c00615}
}
Kostenlos starten →